GlassScriptPhysician profile
Michael S Higginbotham
NPI 1619992377
$1,934.33
in general payments reported to CMS, 2019-2025
23 companies · $38.83 in 2025
The $38.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $244 · 2021: $362 · 2022: $161 · 2023: $68.10 · 2024: $26.30 · 2025: $38.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $133.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $397.75 | 2019-2025 | Breztri |
| Pfizer INC. | $303.69 | 2019-2021 | |
| Novo Nordisk INC | $248.40 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $178.00 | 2019-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $126.69 | 2019-2021 | |
| Abbvie INC. | $116.41 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $94.68 | 2019-2021 | |
| Amgen INC. | $92.61 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.16 | 2019-2022 | |
| Allergan, INC. | $47.17 | 2019 | |
| Supernus Pharmaceuticals, INC. | $40.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.28 | 2019-2020 | |
| Abbott Laboratories | $22.92 | 2025 | Cardiomems |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $22.07 | 2022 | |
| Lilly USA, LLC | $14.92 | 2020 | |
| Corium, LLC | $14.82 | 2022 | |
| Sanofi Pasteur INC. | $12.64 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.60 | 2019 | |
| Genentech USA, INC. | $12.39 | 2019 | |
| Amarin Pharma, INC. | $12.16 | 2019 | |
| Horizon Therapeutics Plc | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Higginbotham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.